Skip to main content
Top
Published in:

Open Access 01-11-2024 | Vulgar Psoriasis | ORIGINAL PAPER

Psoriasis localization patterns in the Swiss Psoriasis Registry (SDNTT) over 11 years: an analysis by sex and age

Authors: Ion Birkenmaier, Lara Valeska Maul, Iker Oyanguren, Christina Sorbe, Fabienne Fröhlich, Christoph Schlapbach, Kristine Heidemeyer, Nikhil Yawalkar, Wolf-Henning Boehncke, Hans-Christian Ring, Jacob P. Thyssen, Alexander Egeberg, Raphael Micheroli, Simon Francis Thomsen, Carlo Mainetti, Antonio Cozzio, Thomas M. Kündig, Mitchell P. Levesque, Alexander Navarini, Julia-Tatjana Maul

Published in: Archives of Dermatological Research | Issue 9/2024

Login to get access

Abstract

Real-world data on anatomically localized psoriasis and its response to systemic therapy across different age-groups and sexes is limited. This study aimed to evaluate the severity and distribution of psoriasis over time in female and male patients receiving systemic therapies, categorized by age within the Swiss psoriasis registry (SDNTT). Patient-data was obtained over 11 years through the SDNTT. The localized Psoriasis Area and Severity Index (locPASI) of the head, trunk, upper and lower extremities was analyzed over two years following the start of systemic non-/biologic treatment. A total of 316 female and 517 male patients were analyzed. Male patients had a higher baseline locPASI for legs, trunk and arms (p < 0.001), but not for the head (p = 0.961). The locPASI for the head in younger female patients (18–40 years) had a higher score than those aged 55 + (p = 0.022) and after two years, middle aged (41–54) showed a lower score compared to younger patients (p = 0.045). Younger male patients revealed a lower score after two years of therapy in the leg- and arm-area compared to older (p = 0.018 and p = 0.048, respectively). Female patients on non-biologics had a fast initial response, converging with male patients’ scores over 24 months. Over 75% locPASI reduction was observed for female head-area (81.4%), male trunk (82.7%) and legs (76.1%). Absolute locPASI ≤ 2 was achieved 3–6 months for all locations with interleukin (IL)-17, IL-12/23 and IL-23-inhibitors, except for the legs of male patients on anti-IL-17 and female patients on anti-IL-12/23 and -IL-23. After two years, male patients did not achieve a locPASI ≤ 2 for any biologic-treatment in the legs, nor for the arms on anti-TNF-α. Significant disparities in localized PASI were observed between female and male patients. The age, sex and severity of distinct localizations should be considered to optimize treatment goals.
Appendix
Available only for authorised users
Literature
1.
go back to reference Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN (2021) Psoriasis. The Lancet 397:1301–1315CrossRef Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN (2021) Psoriasis. The Lancet 397:1301–1315CrossRef
2.
go back to reference Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Team I.a.M.o.P.a.A.C.I.p (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133:377–385PubMedCrossRef Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Team I.a.M.o.P.a.A.C.I.p (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133:377–385PubMedCrossRef
5.
go back to reference Hagg D, Sundstrom A, Eriksson M, Schmitt-Egenolf M (2017) Severity of psoriasis differs between men and women: a study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. Am J Clin Dermatol 18:583–590PubMedPubMedCentralCrossRef Hagg D, Sundstrom A, Eriksson M, Schmitt-Egenolf M (2017) Severity of psoriasis differs between men and women: a study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. Am J Clin Dermatol 18:583–590PubMedPubMedCentralCrossRef
6.
go back to reference Maul JT et al (2021) Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study. Br J Dermatol 185:1160–1168PubMedCrossRef Maul JT et al (2021) Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study. Br J Dermatol 185:1160–1168PubMedCrossRef
7.
go back to reference Maul JT et al (2019) Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. J Eur Acad Dermatol Venereol 33:700–708PubMedCrossRef Maul JT et al (2019) Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. J Eur Acad Dermatol Venereol 33:700–708PubMedCrossRef
8.
go back to reference White D, O’Shea SJ, Rogers S (2012) Do men have more severe psoriasis than women? J Eur Acad Dermatol Venereol 26:126–127PubMedCrossRef White D, O’Shea SJ, Rogers S (2012) Do men have more severe psoriasis than women? J Eur Acad Dermatol Venereol 26:126–127PubMedCrossRef
9.
go back to reference Napolitano M et al (2020) Sex- and gender-associated clinical and psychosocial characteristics of patients with psoriasis. Clin Exp Dermatol 45:705–711PubMedCrossRef Napolitano M et al (2020) Sex- and gender-associated clinical and psychosocial characteristics of patients with psoriasis. Clin Exp Dermatol 45:705–711PubMedCrossRef
10.
go back to reference Ceovic R et al (2013) Psoriasis: female skin changes in various hormonal stages throughout life—puberty, pregnancy, and menopause. Biomed Res Int 2013:571912PubMedPubMedCentralCrossRef Ceovic R et al (2013) Psoriasis: female skin changes in various hormonal stages throughout life—puberty, pregnancy, and menopause. Biomed Res Int 2013:571912PubMedPubMedCentralCrossRef
11.
go back to reference Allam JP et al (2019) Low serum testosterone levels in male psoriasis patients correlate with disease severity. Eur J Dermatol 29:375–382PubMedCrossRef Allam JP et al (2019) Low serum testosterone levels in male psoriasis patients correlate with disease severity. Eur J Dermatol 29:375–382PubMedCrossRef
12.
go back to reference Mowad CM et al (1998) Hormonal influences on women with psoriasis. Cutis 61:257–260PubMed Mowad CM et al (1998) Hormonal influences on women with psoriasis. Cutis 61:257–260PubMed
13.
go back to reference Singh S et al (2018) Effect of age of onset of psoriasis on clinical outcomes with systemic treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Am J Clin Dermatol 19:879–886PubMedPubMedCentralCrossRef Singh S et al (2018) Effect of age of onset of psoriasis on clinical outcomes with systemic treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Am J Clin Dermatol 19:879–886PubMedPubMedCentralCrossRef
14.
go back to reference Guillet C, Seeli C, Nina M, Maul LV, Maul JT (2022) The impact of gender and sex in psoriasis: what to be aware of when treating women with psoriasis. Int J Womens Dermatol 8:e010PubMedPubMedCentralCrossRef Guillet C, Seeli C, Nina M, Maul LV, Maul JT (2022) The impact of gender and sex in psoriasis: what to be aware of when treating women with psoriasis. Int J Womens Dermatol 8:e010PubMedPubMedCentralCrossRef
15.
go back to reference Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M (2022) New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther 22:1431–1433PubMedCrossRef Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M (2022) New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther 22:1431–1433PubMedCrossRef
16.
go back to reference ClinicalTrials.gov Identifier: NCT01706692; Swiss Dermatology Network of Targeted Therapies (SDNTT); 2012. (Bethesda (MD): National Library of Medicine (US). 2000; https://clinicaltrials.gov/study/NCT01706692 - Last Access: January 2024) ClinicalTrials.gov Identifier: NCT01706692; Swiss Dermatology Network of Targeted Therapies (SDNTT); 2012. (Bethesda (MD): National Library of Medicine (US). 2000; https://​clinicaltrials.​gov/​study/​NCT01706692 - Last Access: January 2024)
18.
go back to reference Verardi F et al (2023) Sex differences in adverse events from systemic treatments for psoriasis: a decade of insights from the Swiss Psoriasis Registry (SDNTT). J Eur Acad Dermatol Venereol 38:719–731PubMedCrossRef Verardi F et al (2023) Sex differences in adverse events from systemic treatments for psoriasis: a decade of insights from the Swiss Psoriasis Registry (SDNTT). J Eur Acad Dermatol Venereol 38:719–731PubMedCrossRef
19.
go back to reference Jungo P et al (2016) Superiority in quality of life improvement of biologics over conventional systemic drugs in a swiss real-life psoriasis registry. Dermatology 232:655–663PubMedCrossRef Jungo P et al (2016) Superiority in quality of life improvement of biologics over conventional systemic drugs in a swiss real-life psoriasis registry. Dermatology 232:655–663PubMedCrossRef
20.
go back to reference Maul JT et al (2016) Efficacy and survival of systemic psoriasis treatments: an analysis of the Swiss Registry SDNTT. Dermatology 232:640–647PubMedCrossRef Maul JT et al (2016) Efficacy and survival of systemic psoriasis treatments: an analysis of the Swiss Registry SDNTT. Dermatology 232:640–647PubMedCrossRef
21.
go back to reference Cazzaniga S et al (2019) Linkage between patients’ characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. J Eur Acad Dermatol Venereol 33:2313–2318PubMedCrossRef Cazzaniga S et al (2019) Linkage between patients’ characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. J Eur Acad Dermatol Venereol 33:2313–2318PubMedCrossRef
22.
go back to reference Drach M et al (2019) Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT). Arch Dermatol Res 311:753–760PubMedCrossRef Drach M et al (2019) Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT). Arch Dermatol Res 311:753–760PubMedCrossRef
23.
go back to reference Anzengruber F et al (2019) Smoking does not alter the therapy response to systemic anti-psoriatic therapies: a two-country, multi-centre, prospective. Non-interventional Study Acta Derm Venereol 99:871–877PubMedCrossRef Anzengruber F et al (2019) Smoking does not alter the therapy response to systemic anti-psoriatic therapies: a two-country, multi-centre, prospective. Non-interventional Study Acta Derm Venereol 99:871–877PubMedCrossRef
24.
go back to reference Nielsen ML et al (2023) Predicting psoriatic arthritis in psoriasis patients – a Swiss Registry Study. J Psoriasis Psoriatic Arthr 9(2):41–50CrossRef Nielsen ML et al (2023) Predicting psoriatic arthritis in psoriasis patients – a Swiss Registry Study. J Psoriasis Psoriatic Arthr 9(2):41–50CrossRef
25.
go back to reference Cazzaniga S et al (2019) Linkage between patients’ characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. J Eur Acad Dermatol Venereol 33:2313–2318PubMedCrossRef Cazzaniga S et al (2019) Linkage between patients’ characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. J Eur Acad Dermatol Venereol 33:2313–2318PubMedCrossRef
26.
go back to reference Nast A et al (2020) EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 34:2461–2498PubMedCrossRef Nast A et al (2020) EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 34:2461–2498PubMedCrossRef
27.
go back to reference Nast A et al (2021) EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 35:281–317PubMedCrossRef Nast A et al (2021) EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 35:281–317PubMedCrossRef
28.
go back to reference Fredriksson T, Pettersson U (1978) Severe psoriasis–oral therapy with a new retinoid. Dermatologica 157:238–244PubMedCrossRef Fredriksson T, Pettersson U (1978) Severe psoriasis–oral therapy with a new retinoid. Dermatologica 157:238–244PubMedCrossRef
29.
go back to reference Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE (1999) Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 141:185–191PubMedCrossRef Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE (1999) Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 141:185–191PubMedCrossRef
30.
go back to reference Mann HB, Whitney DR (1947) On a test of whether one of two random variables is stochastically larger than the other. Annals Mathe Statist 18:50–60CrossRef Mann HB, Whitney DR (1947) On a test of whether one of two random variables is stochastically larger than the other. Annals Mathe Statist 18:50–60CrossRef
31.
go back to reference Wilcoxon F (1945) Individual comparisons by ranking methods. Biometrics Bulletin 1:80–83CrossRef Wilcoxon F (1945) Individual comparisons by ranking methods. Biometrics Bulletin 1:80–83CrossRef
32.
go back to reference Fisher RA (1934) Statistical methods for research workers, 5th ed, (Edinburgh, Oliver and Boyd, 1934) Fisher RA (1934) Statistical methods for research workers, 5th ed, (Edinburgh, Oliver and Boyd, 1934)
33.
go back to reference Shapiro SS, Wilk MB (1965) An analysis of variance test for normality (complete samples)†. Biometrika 52:591–611CrossRef Shapiro SS, Wilk MB (1965) An analysis of variance test for normality (complete samples)†. Biometrika 52:591–611CrossRef
34.
go back to reference Student (1908) The Probable Error of a Mean. Biometrika 6:1–25 Student (1908) The Probable Error of a Mean. Biometrika 6:1–25
37.
go back to reference Maul JT et al (2021) Topical treatment of psoriasis vulgaris: The Swiss treatment pathway. Dermatology 237:166–178PubMedCrossRef Maul JT et al (2021) Topical treatment of psoriasis vulgaris: The Swiss treatment pathway. Dermatology 237:166–178PubMedCrossRef
38.
go back to reference Sojević Timotijević Z et al (2017) The impact of changes in psoriasis area and severity index by body region on quality of life in patients with psoriasis. Acta Dermatovenerol Croat 25:215–222PubMed Sojević Timotijević Z et al (2017) The impact of changes in psoriasis area and severity index by body region on quality of life in patients with psoriasis. Acta Dermatovenerol Croat 25:215–222PubMed
39.
go back to reference Blauvelt A et al (2018) Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. J Dermatol Treat 29:220–229CrossRef Blauvelt A et al (2018) Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. J Dermatol Treat 29:220–229CrossRef
40.
go back to reference Hotard RS, Feldman SR, Fleischer AB Jr (2000) Sex-specific differences in the treatment of severe psoriasis. J Am Acad Dermatol 42:620–623PubMedCrossRef Hotard RS, Feldman SR, Fleischer AB Jr (2000) Sex-specific differences in the treatment of severe psoriasis. J Am Acad Dermatol 42:620–623PubMedCrossRef
41.
go back to reference Hägg D, Eriksson M, Sundström A, Schmitt-Egenolf M (2013) The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS One 8:e63619PubMedPubMedCentralCrossRef Hägg D, Eriksson M, Sundström A, Schmitt-Egenolf M (2013) The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS One 8:e63619PubMedPubMedCentralCrossRef
42.
go back to reference Colombo D et al (2022) The CANOVA Study Real-World Evidence of biologic treatments in moderate-severe psoriasis in Italy: a gender perspective. Womens Health Rep (New Rochelle) 3:450–457PubMed Colombo D et al (2022) The CANOVA Study Real-World Evidence of biologic treatments in moderate-severe psoriasis in Italy: a gender perspective. Womens Health Rep (New Rochelle) 3:450–457PubMed
43.
go back to reference Hernández-Fernández CP et al (2021) Effect of sex in systemic psoriasis therapy: differences in prescription, effectiveness and safety in the BIOBADADERM Prospective Cohort. Acta Derm Venereol 101, adv00354 Hernández-Fernández CP et al (2021) Effect of sex in systemic psoriasis therapy: differences in prescription, effectiveness and safety in the BIOBADADERM Prospective Cohort. Acta Derm Venereol 101, adv00354
44.
go back to reference Loft ND, Vaengebjerg S, Halling A-S, Skov L, Egeberg A (2020) Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol 34:1151–1160PubMedCrossRef Loft ND, Vaengebjerg S, Halling A-S, Skov L, Egeberg A (2020) Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol 34:1151–1160PubMedCrossRef
45.
go back to reference Gisondi P et al (2022) Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol 157:1–78PubMed Gisondi P et al (2022) Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol 157:1–78PubMed
46.
go back to reference Nast A et al (2021) German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations. J Dtsch Dermatol Ges 19:934–150PubMed Nast A et al (2021) German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations. J Dtsch Dermatol Ges 19:934–150PubMed
47.
go back to reference Nast A et al (2021) German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 2: Treatment monitoring and specific clinical or comorbid situations. J Dtsch Dermatol Ges 19:1092–1115PubMed Nast A et al (2021) German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 2: Treatment monitoring and specific clinical or comorbid situations. J Dtsch Dermatol Ges 19:1092–1115PubMed
48.
go back to reference Zouboulis CC, Degitz K (2004) Androgen action on human skin – from basic research to clinical significance. Exp Dermatol 13(Suppl 4):5–10PubMedCrossRef Zouboulis CC, Degitz K (2004) Androgen action on human skin – from basic research to clinical significance. Exp Dermatol 13(Suppl 4):5–10PubMedCrossRef
49.
go back to reference Kanda N, Watanabe S (2004) 17beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J Invest Dermatol 123:319–328PubMedCrossRef Kanda N, Watanabe S (2004) 17beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J Invest Dermatol 123:319–328PubMedCrossRef
50.
go back to reference Rachael JT et al (2018) Intentional and unintentional medication non-adherence in psoriasis: the role of patients’ medication beliefs and habit strength. J Investig Dermatol 138:785–794CrossRef Rachael JT et al (2018) Intentional and unintentional medication non-adherence in psoriasis: the role of patients’ medication beliefs and habit strength. J Investig Dermatol 138:785–794CrossRef
Metadata
Title
Psoriasis localization patterns in the Swiss Psoriasis Registry (SDNTT) over 11 years: an analysis by sex and age
Authors
Ion Birkenmaier
Lara Valeska Maul
Iker Oyanguren
Christina Sorbe
Fabienne Fröhlich
Christoph Schlapbach
Kristine Heidemeyer
Nikhil Yawalkar
Wolf-Henning Boehncke
Hans-Christian Ring
Jacob P. Thyssen
Alexander Egeberg
Raphael Micheroli
Simon Francis Thomsen
Carlo Mainetti
Antonio Cozzio
Thomas M. Kündig
Mitchell P. Levesque
Alexander Navarini
Julia-Tatjana Maul
Publication date
01-11-2024
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 9/2024
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-024-03375-5

Other articles of this Issue 9/2024

Archives of Dermatological Research 9/2024 Go to the issue